TEVA - TEVA PHARMACEUTICAL INDUSTRIES LTD

QQQ $ 441.36 $ -1.56 (-0.35 %)

DIA $ 394.82 $ -0.47 (-0.12 %)

SPY $ 520.15 $ -1.36 (-0.26 %)

TLT $ 90.12 $ -0.19 (-0.21 %)

GLD $ 219.15 $ -0.57 (-0.26 %)

Previous Close

$ 16

Open

$ 16.07

Bid

$ 16.33 x 200

Ask

$ 16.34 x 200

Day's Range

$ 16.07 - $ 16.56

52 Week Range

$ 7.09 - $ 16.25

Volume

16,780,250

Average Volume

Market Cap

18.12B

Beta (5Y Monthly)

$ 1.17

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-08-2024	03-31-2024	10-Q
2	02-12-2024	12-31-2023	10-K
3	11-09-2023	09-30-2023	10-Q
4	08-02-2023	06-30-2023	10-Q
5	05-10-2023	03-31-2023	10-Q
6	02-10-2023	12-31-2022	10-K
7	11-03-2022	09-30-2022	10-Q
8	07-27-2022	06-30-2022	10-Q
9	05-03-2022	03-31-2022	10-Q
10	02-09-2022	12-31-2021	10-K
11	10-27-2021	09-30-2021	10-Q
12	07-28-2021	06-30-2021	10-Q
13	04-28-2021	03-31-2021	10-Q
14	02-10-2021	12-31-2020	10-K
15	11-05-2020	09-30-2020	10-Q
16	08-05-2020	06-30-2020	10-Q
17	05-07-2020	03-31-2020	10-Q
18	02-21-2020	12-31-2019	10-K
19	11-07-2019	09-30-2019	10-Q
20	08-07-2019	06-30-2019	10-Q
21	05-02-2019	03-31-2019	10-Q
22	02-19-2019	12-31-2018	10-K
23	11-01-2018	09-30-2018	10-Q
24	08-02-2018	06-30-2018	10-Q
25	05-03-2018	03-31-2018	10-Q
26	02-12-2018	12-31-2017	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Barclays Maintains Overweight on Teva Phar...
05/09/2024 15:42:06

Barclays analyst Balaji Prasad maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target...

generics-player-teva-pharmaceutical-aces-late-stage-schizophrenia-drug-study-stock-shoots-higher

Generics Player Teva Pharmaceutical Aces L...
05/08/2024 17:49:15

Results from the Phase 3 SOLARIS trial of TEV-‘749 for schizophrenia treatment. SteadyTeq technology ensures controlled olanzap...

why-upstart-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Why Upstart Shares Are Trading Lower By Ar...
05/08/2024 17:38:56

louisiana-pacific-posts-upbeat-results-joins-cricut-elanco-animal-american-public-education-and-other-big-stocks-moving-higher-on-wednesday

Louisiana-Pacific Posts Upbeat Results, Jo...
05/08/2024 15:11:22

wall-street-poised-for-muted-open-on-mixed-earnings-with-more-fed-speeches-in-store-analyst-sees-sp-500-crossing-late-march-high

Wall Street Poised For Muted Open On Mixed...
05/08/2024 11:13:23

U.S. stocks are on track for a mixed start on Wednesday as the market digests mixed earnings reports and looks ahead to more sp...

Teva Pharmaceutical Indus Q1 2024 Adj EPS ...
05/08/2024 11:02:23

Teva Pharmaceuticals And Medincell Say Pha...
05/08/2024 10:38:42

The study met its primary endpoint achieving clinically meaningful and statistically significant reductions across all TEV-‘7...

investor-sentiment-falls-further-dow-gains-for-fifth-session

Investor Sentiment Falls Further, Dow Gain...
05/08/2024 07:49:03

uber-lyft-and-3-stocks-to-watch-heading-into-wednesday

Uber, Lyft And 3 Stocks To Watch Heading I...
05/08/2024 07:31:10

will-earnings-cheer-continue-this-week-all-eyes-on-disney-palantir-robinhood-while-reddit-gears-up-for-debut-quarterly-report

Will Earnings Cheer Continue This Week? Al...
05/06/2024 09:25:15

According to FactSet, a financial data analytics firm, 80% of S&P 500 companies have reported earnings so far.

federal-trade-commission-targets-junk-patent-listings-for-diabetes-weight-loss-asthma-drugs-from-companies-like-novo-nordisk-astrazeneca

Federal Trade Commission Targets 'Junk Pat...
05/01/2024 20:11:33

The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, a...

us-supreme-court-declines-to-hear-vanda-pharmaceuticals-case-regarding-invalidation-of-patents-for-its-sleep-disorder-drug-hetlioz

US Supreme Court Declines To Hear Vanda Ph...
04/22/2024 18:37:55

"Supreme Court denies review of Vanda Pharmaceuticals' patent revival attempt for Hetlioz sleep-disorder medication. Le...

'The U.S Supreme Court Has Reportedly Decl...
04/22/2024 16:05:31

https://finance.yahoo.com/news/1-u-supreme-court-rejects-153720025.htmlThe U.S. Supreme Court on Monday declined to hear a bid ...

Alvotech Inks Long-Term Agreement With A S...
04/19/2024 10:11:54

"This new partnership agreement supports our financial guidance and reflects Alvotech's strong commitment to increasing...

Teva Pharmaceuticals Decided That Canada W...
04/18/2024 20:09:37

-SEC Filing

Alvotech, Teva Announce US FDA Approval Of...
04/16/2024 21:33:05

Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of SELARSDI ...

Teva's New Real-World Evidence Presented A...
04/16/2024 12:18:43

Almost 80% of patients with Huntington's disease (HD) chorea were able to achieve optimal dosing within four weeks with the...

Teva Announces Results From Phase 3 Study ...
04/11/2024 12:38:26

Reported Saturday, Teva Pharmaceuticals Pr...
04/08/2024 07:14:12

PK modeling data provide insights into potential dosing conversions and strategies for switching to UZEDY from a long-acting ...

UroGen Pharma Files Patent Infringement Ac...
04/03/2024 12:26:56

UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urot...